Analysis of factors causing hyperkalemia

Internal Medicine

Volumn 46, Issue 12, 2007, Pages 823-829

  Takaichi, Kenmei ^a   Takemoto, Fumi ^a   Ubara, Yoshifumi ^a   Mori, Yasumichi ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Age; Angiotensin converting enzyme inhibitors; Angiotensin II receptor blockers; Diabetes; Hyperkalemia; Renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIABETIC PATIENT; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POTASSIUM BLOOD LEVEL; REFERENCE VALUE; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSALITY; COMORBIDITY; CREATININE; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERKALEMIA; JAPAN; MALE; MIDDLE AGED; POTASSIUM; RECEPTORS, ANGIOTENSIN; REFERENCE VALUES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM;

EID: 34547861647     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6415     Document Type: Article

References (12)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000.
2. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776, 2003.
3. Maschio G, Alberti D, Janin G, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
6. Parving HH, Lehnet H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
8. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. Arch Intern Med 158: 26-32, 1998.
9. Palmer BF. Managing hyperkalemia. caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592, 2004.
10. Castetllino, P, Bia MJ, Defronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney International 37: 793-798, 1990.
11. Jarman PR, Kehely AM, Mather HM. Hyperkalemia in diabetes: prevalence and associations. Postgrad Med J 71: 551-552, 1995.
12. Ahuja TS, Freeman D, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 20: 268-272, 2000.